A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2012

At a glance

  • Drugs CCX 354 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms CARAT-1
  • Most Recent Events

    • 09 Nov 2010 Results were reported at the Annual American College of Rheumatology Meeting (ACR), according to a ChemoCentryx media release.
    • 19 Jul 2010 Actual end date changed from 30 Mar 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top